期刊
THERANOSTICS
卷 1, 期 -, 页码 154-188出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno/v01p0154
关键词
Integrin-targeted therapeutics; abciximab; tirofiban; eptifibatide; natalizumab; cilengitide; abegrin; acute coronary syndromes; Multiple Sclerosis; Crohn's Disease; cancer; angiogenesis; osteoporosis; age related macular degeneration; integrin-targeted small molecules; integrin-targeted peptides; integrin-targeted therapeutic antibodies
资金
- National Cancer Institutes, National Institutes of Health [RO1CA120188]
Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据